Article ID Journal Published Year Pages File Type
5685515 American Journal of Kidney Diseases 2017 8 Pages PDF
Abstract
Switching patients from a CNI to belatacept may represent a safe approach to immunosuppression and is being further explored in an ongoing phase 3b trial.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Nephrology
Preview
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial
Authors
, , , , , , , , , , , , , ,